Atrial fibrillation and Paranasal sinus hypersecretion
Paranasal sinus hypersecretion is found among people with Atrial fibrillation, especially for people who are male, 60+ old.
The study analyzes which people have Paranasal sinus hypersecretion with Atrial fibrillation. It is created by eHealthMe based on reports of 14 people who have Atrial fibrillation from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
14 people who have Atrial Fibrillation and Paranasal Sinus Hypersecretion are studied.
What is Atrial fibrillation?
Atrial fibrillation (fibrillation of the muscles of the atria of the heart) is found to be associated with 3,584 drugs and 3,440 conditions by eHealthMe.
What is Paranasal sinus hypersecretion?
Paranasal sinus hypersecretion is found to be associated with 703 drugs and 386 conditions by eHealthMe.
Number of Paranasal sinus hypersecretion in Atrial fibrillation reports submitted per year:
Gender of people who have Atrial Fibrillation and experienced Paranasal Sinus Hypersecretion *:
- female: 50 %
- male: 50 %
Age of people who have Atrial Fibrillation and experienced Paranasal Sinus Hypersecretion *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 8.33 %
- 50-59: 0.0 %
- 60+: 91.67 %
Common co-existing conditions for these people *:
- Ankylosing Spondylitis (type of arthritis affecting the spine): 4 people, 28.57%
- Stress And Anxiety: 3 people, 21.43%
- Essential Tremor: 3 people, 21.43%
- High Blood Pressure: 3 people, 21.43%
- Vulvovaginal Pruritus (vulvovaginal severe itching): 2 people, 14.29%
- High Blood Cholesterol: 2 people, 14.29%
- Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 14.29%
- Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 14.29%
- Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 2 people, 14.29%
- Vulvovaginal Candidiasis (vulvovaginal infection by fungi): 2 people, 14.29%
Common drugs taken by these people *:
- Coumadin: 5 people, 35.71%
- Humira: 5 people, 35.71%
- Diovan: 5 people, 35.71%
- Combivent: 3 people, 21.43%
- Premarin: 3 people, 21.43%
- Sertraline: 3 people, 21.43%
- Aspirin: 3 people, 21.43%
- Spiriva: 3 people, 21.43%
- Protonix: 3 people, 21.43%
- Tylenol: 3 people, 21.43%
Common symptoms for these people *:
- Muscle Spasms (muscle contraction): 6 people, 42.86%
- Back Pain: 5 people, 35.71%
- Dizziness: 5 people, 35.71%
- Diarrhea: 4 people, 28.57%
- Oropharyngeal Pain: 4 people, 28.57%
- Weight Increased: 4 people, 28.57%
- Fatigue (feeling of tiredness): 4 people, 28.57%
- Joint Pain: 4 people, 28.57%
- Breathing Difficulty: 4 people, 28.57%
- Coronary Artery Occlusion (complete obstruction of blood flow in a coronary artery): 3 people, 21.43%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Paranasal sinus hypersecretion?Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
- Tesic D, Kostic M, Paunovic D, Jankovic SM, "Analysis of the cost–effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia", Kardiologia Polska (Polish Heart Journal), 2016 Jan .
- Bolognesi M, Bolognesi D, "Medicine Ciprofloxacin-induced paroxysmal atrial fibrillation", , 2014 Mar .
- Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .
- Bolognesi M, Bolognesi D, "Ciprofloxacin-induced paroxysmal atrial fibrilation", OA Case Reports, 2012 Jan .
Treatments, associated drugs and conditions:
COVID vaccines that are related to Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion in Moderna COVID Vaccine
- Paranasal sinus hypersecretion in Pfizer BioNTech Covid Vaccine
- Paranasal sinus hypersecretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Paranasal sinus hypersecretion:
All the drugs that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (703 drugs)
Common conditions associated with Paranasal sinus hypersecretion:
All the conditions that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (386 conditions)
How the study uses the data?
The study is based on Paranasal sinus hypersecretion and Atrial fibrillation, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Atarax and Pelvic Venous Thrombosis - now
- Spiriva and Kidney Duplex - 4 seconds ago
- Novalgin and Pre-Existing Condition Improved - 5 seconds ago
- Vitamin D2 and Bosulif drug interaction - 6 seconds ago
- Vivelle-Dot and Blood Pressure Fluctuation - 14 seconds ago
- Gemzar and Vena Cava Embolism - 15 seconds ago
- Essential Thrombocythaemia and Cardiac Failure Congestive - 15 seconds ago
- Klonopin and Aldara drug interaction - 16 seconds ago
- Escitalopram Oxalate and Acoustic Neuroma - 17 seconds ago
- Exforge Hct and Acute Hepatic Failure - 19 seconds ago